GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
The initial product of that enzyme is the peracid of ureidoacrylic acid, to which it spontaneously converts. Pyrimidine oxygenase can also use thymine as a substrate and in that case its product is (Z)-2-methylureidoacrylic acid:
Tarlov concluded that such cysts, though often overlooked during standard imaging or surgery, could produce clinically significant symptoms and should be considered in cases of unexplained sciatic pain. He published these findings in the paper "Cysts (Perineurial) of the Sacral Roots: Another Cause (Removable) of Sciatic Pain" (1948). In 1952, Tarlov published his third paper on perineurial cysts, titled "Cysts of the Sacral Nerve Roots: Clinical Significance and Pathogenesis". In this work, he acknowledged the limitations of his earlier cadaver studies due to incomplete medical records, noting that the symptomatic relevance of the cysts was initially unclear. The paper presented detailed accounts of two surgical cases from 1950 and 1951 in which sacral nerve root cysts were associated with neurological symptoms. The first patient, a 28-year-old man with progressive numbness, urinary incontinence, and sexual dysfunction, was found to have bilateral S2 cysts; surgical removal of the right cyst and drainage of the left halted symptom progression and improved bladder function. The second case involved a 70-year-old woman with paresthesia in the right leg and vaginal area, foot weakness, and sacral tenderness, in whom four cysts were discovered on the S2 and S3 nerve roots. Partial excision led to improvement in foot strength and partial symptom relief. Tarlov also discussed two post-mortem cases in which subarachnoid hemorrhages and sacral cysts coexisted, prompting the hypothesis that the cysts might occasionally form secondary to hemorrhagic damage to nerve roots.
The side corridors are structurally highly sophisticated and remain visible to this day. A low platform runs along the external wall of each corridor, on which rows of statues were displayed, with murals behind them including the figure of the painter in tunic and boots. Above them, the top of each corridor formed a high vault, equipped with a lunette on the southern side, and decorated over its length with rows of devatas behind a balustrade, standing around a Buddha Maitreya, and on top of them landscapes with rhombus losange designs with monks, animals, trees and ponds, of the type seen in vault of the Cave of the Hippocampi (Cave 118).
Sources: en.wikipedia.org
=== Butterfly === An original incarnation of Psylocke named O-Chiyo Braddock appears in 5 Ronin. This version is the English-Japanese orphan daughter of a local Japanese woman who died when she was a baby and an English expat trader who committed suicide when she was a child after his business failed. After being forced into the yoshiwara to survive, O-Chiyo grows up to become the top-ranked prostitute, codenamed "Butterfly", in a high-end brothel. She later crosses paths with a Ronin called the Wolverine, who becomes her regular customer.
== History == Potassium sulfate (K2SO4) has been known since early in the 14th century. It was studied by Glauber, Boyle, and Tachenius. In the 17th century, it was named arcanuni or sal duplicatum, as it was a combination of an acid salt with an alkaline salt. It was also known as vitriolic tartar and Glaser's salt or sal polychrestum Glaseri after the pharmaceutical chemist Christopher Glaser who prepared it and used medicinally. Known as arcanum duplicatum ("double secret") or panacea duplicata in pre-modern medicine, it was prepared from the residue (caput mortuum) left over from the production of aqua fortis (nitric acid, HNO3) from nitre (potassium nitrate, KNO3) and oil of vitriol (sulphuric acid, H2SO4) via Glauber's process:
While nylon was marketed as the durable and indestructible material of the people, it was sold at about one-and-a-half times the price of silk stockings ($4.27 per pound of nylon versus $2.79 per pound of silk). Sales of nylon stockings were strong in part due to changes in women's fashion. As Lauren Olds explains: "by 1939 [hemlines] had inched back up to the knee, closing the decade just as it started off". The shorter skirts were accompanied by a demand for stockings that offered fuller coverage without the use of garters to hold them up. However, as of February 11, 1942, nylon production was redirected from being a consumer material to one used by the military. DuPont's production of nylon stockings and other lingerie stopped, and most manufactured nylon was used to make parachutes and tents for World War II. Although nylon stockings already made before the war could be purchased, they were generally sold on the black market for as high as $20. Once the war ended, the return of nylon was awaited with great anticipation. Although DuPont projected yearly production of 360 million pairs of stockings, there were delays in converting back to consumer rather than wartime production. In 1946, the demand for nylon stockings could not be satisfied, which led to the nylon riots. In one instance, an estimated 40,000 people lined up in Pittsburgh to buy 13,000 pairs of nylons. In the meantime, women cut up nylon tents and parachutes left from the war in order to make blouses and wedding dresses.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。